The stock of Dynavax Technologies Corp (NASDAQ: DVAX) has increased by 1.87 when compared to last closing price of 11.79. Despite this, the company has experienced a 1.69% gain in its stock price over the last five trading sessions. prnewswire.com reported 2024-10-29 that EMERYVILLE, Calif., Oct. 29, 2024 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that its Board of Directors has adopted a limited-duration stockholder rights plan, effective immediately (the “Rights Plan”).
Is It Worth Investing in Dynavax Technologies Corp (NASDAQ: DVAX) Right Now?
Dynavax Technologies Corp (NASDAQ: DVAX) has a higher price-to-earnings ratio of 109.88x compared to its average ratio. DVAX has 36-month beta value of 1.34. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DVAX is 130.41M, and currently, short sellers hold a 13.08% ratio of that float. The average trading volume of DVAX on November 06, 2024 was 2.17M shares.
DVAX’s Market Performance
DVAX stock saw an increase of 1.69% in the past week, with a monthly gain of 11.51% and a quarterly increase of 11.72%. The volatility ratio for the week is 2.43%, and the volatility levels for the last 30 days are 2.79% for Dynavax Technologies Corp (DVAX). The simple moving average for the last 20 days is 7.99% for DVAX stock, with a simple moving average of 3.32% for the last 200 days.
Analysts’ Opinion of DVAX
Many brokerage firms have already submitted their reports for DVAX stocks, with Goldman repeating the rating for DVAX by listing it as a “Neutral.” The predicted price for DVAX in the upcoming period, according to Goldman is $20 based on the research report published on February 01, 2024 of the current year 2024.
JMP Securities, on the other hand, stated in their research note that they expect to see DVAX reach a price target of $22. The rating they have provided for DVAX stocks is “Mkt Outperform” according to the report published on September 27th, 2022.
Goldman gave a rating of “Buy” to DVAX, setting the target price at $38 in the report published on January 06th of the previous year.
DVAX Trading at 8.33% from the 50-Day Moving Average
After a stumble in the market that brought DVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.99% of loss for the given period.
Volatility was left at 2.79%, however, over the last 30 days, the volatility rate increased by 2.43%, as shares surge +12.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.35% upper at present.
During the last 5 trading sessions, DVAX rose by +1.69%, which changed the moving average for the period of 200-days by -15.30% in comparison to the 20-day moving average, which settled at $11.12. In addition, Dynavax Technologies Corp saw -14.09% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DVAX starting from CANO FRANCIS, who sale 3,615 shares at the price of $11.93 back on May 31 ’24. After this action, CANO FRANCIS now owns 36,905 shares of Dynavax Technologies Corp, valued at $43,127 using the latest closing price.
Burgess Justin, the Chief Accounting Officer of Dynavax Technologies Corp, sale 20,526 shares at $12.78 during a trade that took place back on Mar 01 ’24, which means that Burgess Justin is holding 0 shares at $262,322 based on the most recent closing price.
Stock Fundamentals for DVAX
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.82 for the gross margin
The net margin for Dynavax Technologies Corp stands at 0.07. The total capital return value is set at -0.01. Equity return is now at value 2.82, with 1.76 for asset returns.
Based on Dynavax Technologies Corp (DVAX), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at 0.17. The debt to equity ratio resting at 0.35. The interest coverage ratio of the stock is -1.97.
Currently, EBITDA for the company is 20.98 million with net debt to EBITDA at 10.4. When we switch over and look at the enterprise to sales, we see a ratio of 6.87. The receivables turnover for the company is 3.99for trailing twelve months and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.18.
Conclusion
To put it simply, Dynavax Technologies Corp (DVAX) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
